Current Trends in Pharmacy and Pharmaceutical Chemistry

Online ISSN: 2582-5062

Current Trends in Pharmacy and Pharmaceutical Chemistry is the official Journal of Ateos Foundation of Science Education and Research, hosted and Managed IP Innovative Publications Pvt. Ltd, New Delhi, India. Current Trends in Pharmacy and Pharmaceutical Chemistry is an open access, peer-reviewed quarterly international journal publishing since 2019 and is published under auspices of the Ateos Foundation of Science Education and Research. It aims to uplift researchers, scholars, academicians, and professionals in all academic and scientific disciplines. more...

  • Article highlights
  • Article tables
  • Article images

Article statistics

Viewed: 296

PDF Downloaded: 147


Get Permission Gaikwad: Review of indole, A versatile pharmacophoric moiety


Introduction

Indole is a heterocyclic aromatic compound composed of a bicyclic structure. It consists of a six-membered benzene ring fused to a five-membered pyrrole ring, resulting in a unique and intriguing chemical structure. Found in various natural products such as serotonin, tryptophan, and auxins.

  1. Reactivity: Reacts with electrophiles, nucleophiles, radicals, and metals to afford a wide range of substituted indole derivatives.

  2. Functional Groups: Indole derivatives can have a wide range of functional groups, including halogens, amines, ketones, esters, and more.

Table 0

Properties

Chemical Formula

C8H7N

Molecular Mass

117.124 g/mol

Appearance

White Solid turn yellow on exposure to light.

Melting Point

52-54 degrees Celsius

Acidity(pKa)

16.2

Basicity(pKb)

17.6

Indole Exhibits antimicrobial, anticancer, anti-inflammatory, and neuromodulator activities.

Review

Drugs containing Indole Ring have been reviewed in this section.

Drugs Containing indole ring/derivatives:

  1. Anticancer

  2. NSAID

  3. Antiemetic

  4. ED (Erectile Dysfunction Drugs)

  5. Antimigraine agents

  6. Antiviral

Anticancer Drugs

There are several U.S FDA has recently approved indole based anticancer agents such as

  1. Vinblastine

  2. Panobinostat

  3. Alectinib

  4. Sunitinib

  5. Osimertinib

  6. Nintedanib

Vinblastine

Figure 0
https://s3-us-west-2.amazonaws.com/typeset-prod-media-server/d6e5bb79-d48e-46f7-a3c7-3d40f4715ba0image1.png

Vinblastine sulfate 1, 2 has the molecular formula C46H58O9N4•H2SO4 and it is a dimeric alkaloid containing both indole and dihydroindole moieties.

IUPAC: Dimethyl(2β,3β,4β,5α,12β,19α)-15-[(5S,9S)-5-ethyl-5-hydroxy-9-(methoxycarbonyl)-1,4,5,6,7,8,9,10-octahydro-2H-3,7-methanoazacycloundecino[5,4-b]indol-9-yl]-3-hydroxy-16-methoxy-1-methyl-6,7-didehydroaspidospermidine-3,4-dicarboxylate.

MOA: It binds to microtubular proteins in the mitotic spindle, thereby preventing cell division during metaphase. It also interferes with amino acid metabolism by inhibiting glutamic acid utilization and preventing purine synthesis, citric acid cycle, and urea formation.

Marketed Preparation

Figure 0
https://s3-us-west-2.amazonaws.com/typeset-prod-media-server/d6e5bb79-d48e-46f7-a3c7-3d40f4715ba0image2.png

Other anticancer drugs

Panobinostat

Figure 0
https://s3-us-west-2.amazonaws.com/typeset-prod-media-server/d6e5bb79-d48e-46f7-a3c7-3d40f4715ba0image3.png

Panobinostat 3, 4 sold under the brand name Farydak, is a medication used for the treatment of multiple myeloma. It is a hydroxamic acid and acts as a non-selective histone deacetylase inhibitor (pan-HDAC inhibitor). Panobinostat is used in combination with the anti-cancer drug bortezomib and the corticoid dexamethasone for the treatment of multiple myeloma in adults who had received at least two previous treatments, including bortezomib and an immunomodulatory agent.

Alectinib

Figure 0
https://s3-us-west-2.amazonaws.com/typeset-prod-media-server/d6e5bb79-d48e-46f7-a3c7-3d40f4715ba0image4.png

IUPAC: 9-Ethyl-6,6-dimethyl-8-[4-(morpholin-4-yl)piperidin-1-yl]-11-oxo-6,11-dihydro-5H- benzo[b]carbazole-3-carbonitrile

Alectinib 5, 6 is indicated for the first-line treatment of adults with anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC); 5 and for the treatment of adults with ALK‑positive advanced NSCLC previously treated with crizotinib.

Sunitinib

Figure 0
https://s3-us-west-2.amazonaws.com/typeset-prod-media-server/d6e5bb79-d48e-46f7-a3c7-3d40f4715ba0image5.png

Sunitinib 7, 8 sold under the brand name Sutent, is an anti-cancer medication. It is a small-molecule, multi-targeted receptor tyrosine kinase (RTK) inhibitor that was approved by the FDA for the treatment of renal cell carcinoma (RCC) and imatinib-resistant gastrointestinal stromal tumor (GIST) in January 2006. Sunitinib was the first cancer drug simultaneously approved for two different indications.

Osimertinib

Figure 0
https://s3-us-west-2.amazonaws.com/typeset-prod-media-server/d6e5bb79-d48e-46f7-a3c7-3d40f4715ba0image6.png

Osimertinib 9, 10 is used to treat locally advanced or metastatic non-small-cell lung cancer (NSCLC), if the cancer cells are positive for the T790M mutation in the gene coding for EGFR or for activating EGFR mutations. The T790M mutation may be de novo or acquired following first-line treatment with other EGFR tyrosine kinase inhibitors, such as gefitinib, erlotinib, and afatinib.

Nintedanib

Figure 0
https://s3-us-west-2.amazonaws.com/typeset-prod-media-server/d6e5bb79-d48e-46f7-a3c7-3d40f4715ba0image7.png

Nintedanib11, 12 It is used in idiopathic pulmonary fibrosis and Lung Cancer.

NSAID

Indomethacin

Figure 0
https://s3-us-west-2.amazonaws.com/typeset-prod-media-server/d6e5bb79-d48e-46f7-a3c7-3d40f4715ba0image8.png

IUPAC: 2-{1-[(4-Chlorophenyl) carbonyl]-5-methoxy-2-methyl-1H-indol-3-yl}acetic acid

Indomethacin 13, 14 is a nonsteroidal anti-inflammatory drug (NSAID) used to treat mild to moderate acute pain and relieve symptoms of arthritis (osteoarthritis and rheumatoid arthritis) or gout, such as inflammation, swelling, stiffness, and joint pain.

MOA: Inhibits the synthesis of prostaglandins and prostaglandin synthesis.

Marketed Preparation

Figure 0
https://s3-us-west-2.amazonaws.com/typeset-prod-media-server/d6e5bb79-d48e-46f7-a3c7-3d40f4715ba0image9.png

Antiemetic

Ondansetron

Figure 0
https://s3-us-west-2.amazonaws.com/typeset-prod-media-server/d6e5bb79-d48e-46f7-a3c7-3d40f4715ba0image10.png

IUPAC: (RS)-9-Methyl-3-[(2-methyl-1H-imidazol-1-yl)methyl]-2,3-dihydro-1H-carbazol-4(9H)-one

Ondansetron15, 16 is a selective antagonist of the 5-hydroxytryptamine3 (5-HT3) receptors and is a very effective agent in the prevention and treatment of nausea and vomiting. Ondansetron is used to prevent nausea and vomiting caused by cancer chemotherapy, radiation therapy, and surgery. It works by blocking the action of serotonin, a natural substance that may cause nausea and vomiting

Marketed preparations

Figure 0
https://s3-us-west-2.amazonaws.com/typeset-prod-media-server/d6e5bb79-d48e-46f7-a3c7-3d40f4715ba0image11.png

ED (Erectile Dysfunction Drugs)

Tadalafil

Figure 1
https://s3-us-west-2.amazonaws.com/typeset-prod-media-server/d6e5bb79-d48e-46f7-a3c7-3d40f4715ba0image12.png

IUPAC: (6R,12aR)-6-(1,3-benzodioxol-5-yl)-2-methyl-2,3,6,7,12,12a-hexahydropyrazino [1',2':1,6] pyrido[3,4-b]indole-1,4-dione

MOA: Tadalafil 17, 18 is in a class of medications called phosphodiesterase (PDE) inhibitors. It works to treat erectile dysfunction by increasing blood flow to the penis during sexual stimulation.

Marketed Preparation

Figure 0
https://s3-us-west-2.amazonaws.com/typeset-prod-media-server/d6e5bb79-d48e-46f7-a3c7-3d40f4715ba0image13.png

Antimigraine agents

MOA: Triptans group drugs act as antimigraine agents by selectively binding to the serotonin receptors 5-HT1B and 5-HT1D

Almotriptan 19

Figure 0
https://s3-us-west-2.amazonaws.com/typeset-prod-media-server/d6e5bb79-d48e-46f7-a3c7-3d40f4715ba0image14.png

IUPAC: N, N-dimethyl-2-[5-(pyrrolidin-1-ylsulfonylmethyl)-1H-indol-3-yl] ethanamine

Marketed Preparation

Figure 0
https://s3-us-west-2.amazonaws.com/typeset-prod-media-server/d6e5bb79-d48e-46f7-a3c7-3d40f4715ba0image15.png

Naratriptan 20

Figure 0
https://s3-us-west-2.amazonaws.com/typeset-prod-media-server/d6e5bb79-d48e-46f7-a3c7-3d40f4715ba0image16.png

IUPAC: N-methyl-2-[3-(1-methylpiperidin-4-yl)-1H-indol-5-yl] ethane-1-sulfonamide hydrochloride.

Marketed Preparation

Figure 0
https://s3-us-west-2.amazonaws.com/typeset-prod-media-server/d6e5bb79-d48e-46f7-a3c7-3d40f4715ba0image17.png

Rizatriptan 21

Figure 0
https://s3-us-west-2.amazonaws.com/typeset-prod-media-server/d6e5bb79-d48e-46f7-a3c7-3d40f4715ba0image18.png

IUPAC: - N, N-Dimethyl-2-[5-(1H-1,2,4-triazol-1-ylmethl)- y1H-indol-3-yl]ethanamine

Marketed Preparation

Figure 0
https://s3-us-west-2.amazonaws.com/typeset-prod-media-server/d6e5bb79-d48e-46f7-a3c7-3d40f4715ba0image19.png

Frovatriptan22

Figure 0
https://s3-us-west-2.amazonaws.com/typeset-prod-media-server/d6e5bb79-d48e-46f7-a3c7-3d40f4715ba0image20.png

IUPAC: (+) -(R)-3-Methylamino-6-carboxamido-1,2,3,4-tetrahydrocarbazole

Marketed Preparation

Figure 0
https://s3-us-west-2.amazonaws.com/typeset-prod-media-server/d6e5bb79-d48e-46f7-a3c7-3d40f4715ba0image21.png

Antiviral

Arbidol23

Figure 0
https://s3-us-west-2.amazonaws.com/typeset-prod-media-server/d6e5bb79-d48e-46f7-a3c7-3d40f4715ba0image22.png

IUPAC: (2S,3R,4R,5R)-Hexane-1,2,3,4,5,6-hexol

Conclusion

Witness the broad spectrum of therapeutic applications of indole. From treating psychiatric disorders to combating microbial infections, indole-based drugs offer promising avenues for current and future medical treatments.

Source of Funding

None.

Conflict of Interest

None.

Acknowledgment

The author VG thanks, his UG Supervisor, Professor (UG) and Research Head, Prof. Dr. Amit G. Nerkar for his guidance and due moral support.

References

1 

B Gigant C Wang RB Ravelli F Roussi MO Steinmetz PA Curmi Structural basis for the regulation of tubulin by vinblastineNature2005435704151941

2 

GH Du YW Zhang XY Kong JH Wang GH Du Vinblastine and vincristine. Nat Small Mol Drugs Plants20185518

3 

G Jones Kp Panobinostat: first global approvalDrugs201575695704

4 

JP Laubach P Moreau JF San-Miguel PG Richardson Panobinostat for the treatment of multiple myeloma.Clin Cancer Res201521476773

5 

M Herden C F Waller Alectinib AlectinibSmall Mol Oncol201824756

6 

T Hida H Nokihara M Kondo YH Kim K Azuma T Seto Alectinib versus crizotinib in patients with ALK-positive non-small-cell lung cancer (J-ALEX): an open-label, randomised phase 3 trial.Lancet20173902939

7 

BI Rini Expert opinion on pharmacotherapy of narcolepsyExp Opin Pharmacother20078235969

8 

ED Deeks GM Keating SunitinibDrugs200666225566

9 

U Malapelle B Ricciuti S Baglivo F Pepe P Pisapia P Anastasi OsimertinibSmall Mol Oncol201825776

10 

JC Soria Y Ohe J Vansteenkiste T Reungwetwattana B Chewaskulyong KH Lee Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancerNew Engl J Med2018378211338

11 

GJ Roth R Binder F Colbatzky C Dallinger R Schlenker-Herceg F Hilberg Nintedanib: from discovery to the clinicJ Med Chem2015583105363

12 

L Richeldi D Bois RM Raghu G Azuma A Brown KK Costabel Efficacy and safety of nintedanib in idiopathic pulmonary fibrosisNew Engl J Med201437022207182

13 

S Lucas The pharmacology of indomethacin. Headache: J Head Face Pain20165643682

14 

L Helleberg Clinical pharmacokinetics of indomethacinClin Pharmacokinetics19816424558

15 

F Roila Del Favero Ondansetron clinical pharmacokineticsClin Pharmacokinetics199529295109

16 

MI Wilde A Markham Ondansetron: a review of its pharmacology and preliminary clinical findings in novel applicationsDrugs19965277394

17 

MP Curran GM Keating TadalafilDrugs200363220315

18 

CC Carson J Rajfer I Eardley S Carrier JS Denne DJ Walker The efficacy and safety of tadalafil: an updateBJU Int2004939127681

19 

JM Palacios X Rabasseda J Castañer AlmotriptanDrugs Future1999244

20 

R Salonen NaratriptanInt J Clin Pract1999535528

21 

MJ Láinez Rizatriptan in the treatment of migraine.Neuropsychiatric Disease Treat2006224759

22 

F Markus K Mikko Frovatriptan review.Frovatriptan Rev Expert Opin Pharmacother20078302962

23 

J Blaising SJ Polyak EI Pécheur Arbidol as a broad-spectrum antiviral: an update.Antiviral Res2014107849410.1016/j.antiviral.2014.04.006



jats-html.xsl


This is an Open Access (OA) journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.

Article type

Review Article


Article page

34-40


Authors Details

Vijay Gaikwad


Article History

Received : 23-04-2024

Accepted : 01-05-2024


Article Metrics


View Article As

 


Downlaod Files